Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Monoclonal Antibodies Obesity Treatments Alzheimer's Disease Combination Therapy Eli Lilly GLP-1 Drugs Novo Nordisk Obesity Treatment Weight Loss Drugs

FDA Clears Higher-Dose Wegovy as Lilly’s Retatrutide Advances and India Readies Semaglutide Generics

A fast‑track voucher cut FDA review to 54 days, positioning an April U.S. launch as Indian patents lapse and competition intensifies.

Corcept Hit With Securities Class Action Over Relacorilant FDA Rebuff as Lead-Plaintiff Deadline Nears

FDA Approves J&J’s Icotyde, First Oral IL-23 Receptor Blocker for Plaque Psoriasis

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

Artelo Secures Fully Funded Investigator-Led Glaucoma Trial With Belfast Health Trust

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety and Launch Claims

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Legend Biotech Reports 66% Q4 CARVYKTI Sales Surge as Capacity Ramps and 2026 Profit Nears

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

CHMP Backs Xolremdi for WHIM Syndrome Under Exceptional Circumstances

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

EMA Panel Backs Conditional EU Approval for Ojemda in Pediatric Low-Grade Glioma

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III